Release

ADVENTRX Pharmaceuticals to Present at the 10th Annual BIO Investor Forum Conference on October 26

SAN DIEGO, Oct. 19, 2011 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 10th Annual BIOInvestor Forum Conference on Wednesday, October 26, 2011 at 1:30 p.m. Pacific time, in the Sea Cliff Salon at the Palace Hotel in San Francisco.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at http://www.adventrx.com/. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates. The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a detergent-free formulation of the blockbuster drug Taxotere®, which recently went off-patent. The Company is seeking a partner or outside investor for its Exelbine program. More information can be found on the Company's web site at http://www.adventrx.com/.

SOURCE ADVENTRX Pharmaceuticals, Inc.